Medigene AG

The article content provided does not contain any text to summarize.

Medigene AG updates its strategy to focus on high-potential R&D programs, leading to a 40% workforce reduction in 2025. The company will delay the MDG1015 clinical trial and pause other autologous cell therapy programs, prioritizing 3S TCR generation and TCR-guided T cell engager MDG3010 with WuXi Biologics. Medigene aims to enhance value for patients, investors, and partners.

Medigene AG reported Q3 2024 financial results, focusing on TCR-guided therapies for cancer. Highlights include a strategic partnership with WuXi Biologics for TCR-TCEs, FDA clearance for MDG1015, and a 2:1 share capital reduction. The company secured a EUR 15 million financing option and maintains a cash runway into July 2025.